Merck Sharp & Dohme LLC

Essais recensés

• Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Recrutement en cours
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Recrutement en cours
• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)Recrutement en cours

Annonces en ligne

Aucune annonce en ligne actuellement.